Molecular laboratories now see denial rates near 27.5%, and the not-otherwise-specified code at the center of it is losing coverage plan by plan. MolDX limits, Cigna's NOS exclusion, the BCBS removals, the $35 rate and the PAMA cuts resuming in January — and what actually gets the claims paid.

Five insurers are leaving Medicare Advantage markets and 25 million people have lost Medicaid. For a laboratory, every one of those moves is an eligibility event that surfaces weeks later as a misrouted claim with a filing deadline attached.

Five new UnitedHealthcare lab policies, twenty-four at BCBS Texas, a new CPT code set and a $1.6 billion enforcement sweep in one month. Payer policy now ships on a release cycle, and it lands in the remittance file as denials with a deadline.

Regulators expected 17,000 No Surprises Act disputes a year; there were 2.5 million in 2025, and the parties who filed won 85% of them. Laboratories are absent from the docket — and 74.6% of their denied claims are never touched again.

Payers have published their prior-authorization denial rates for the first time, and the largest carrier has dropped the requirement from 1,700 codes. Read at the code level, the laboratory relief is thirty PLA codes — and the review has moved downstream of the specimen.

On a $40 million denied book, the categories an appeal can win account for less than half a percent of recoverable dollars. Almost everything else is recovered by a corrected claim, a reroute or a refile — and the market sells appeals.

Three frontier models, the same denied claims, the same tools and prompts, and a 5.2× spread in cost per recovery. The largest economic move was not the choice of model. It was context engineering.

A composite analysis of Recovr's production customer base — 3.38 million claims and 1.76 million denials over 12 months — reveals which denied dollars are truly recoverable and what AI agents do about them, with the live production record through July 2026.

Seven practices for handling overdue claims with AI agents, from a pipeline that screened 22,000 silent claims across a national collection of more than 12,000 physicians, resent 1,401 of them, and captured the payers' verdicts within a day.